" class="no-js "lang="en-US"> Rodolphe Clerval - Medtech Alert
Tuesday, May 20, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Rodolphe Clerval

Rodolphe Clerval

About Rodolphe Clerval

Biotech industry executive with 20 years of experience in strategy, business development and corporate finance.

Related Story

Appointments

 Coave Therapeutics Strengthens Leadership Team with the Appointments of Catherine Mathis as Vice President Regulatory Affairs and Julien Berger as Head of Legal Affairs | Pharmtech Focus

Coave Therapeutics Strengthens Leadership Team with the Appointments of Catherine Mathis as Vice President Regulatory Affairs and Julien Berger as Head of Legal Affairs

September 6 2022

Coave Therapeutics (‘Coave’), a clinical-stage biotechnology company focused on developing life-changing gene therapies for CNS […]

Central Nervous System

 ABL and Coave Therapeutics Collaborate to Develop Manufacturing Processes and Create Joint Capabilities for Process Development | Pharmtech Focus

ABL and Coave Therapeutics Collaborate to Develop Manufacturing Processes and Create Joint Capabilities for Process Development

June 10 2022

Coave Therapeutics (‘Coave’), a clinical-stage biotechnology company focused on developing life-changing gene therapies for CNS […]

Appointments

 Coave Therapeutics Strengthens Leadership Team with the Appointments of Thomas Blaettler MD as Chief Medical Officer and Patricia Françon PhD as Chief Operating Officer | Pharmtech Focus

Coave Therapeutics Strengthens Leadership Team with the Appointments of Thomas Blaettler MD as Chief Medical Officer and Patricia Françon PhD as Chief Operating Officer

November 15 2021

Coave Therapeutics (‘Coave‘), a clinical-stage biotechnology company focused on developing life-changing gene therapies in rare […]

Central Nervous System

 Coave Therapeutics Closes €33 million ($39 million) Series B Financing to Develop its Gene Therapy Pipeline and Next-Generation Vectors based on its AAV-Ligand Conjugate Platform | Pharmtech Focus

Coave Therapeutics Closes €33 million ($39 million) Series B Financing to Develop its Gene Therapy Pipeline and Next-Generation Vectors based on its AAV-Ligand Conjugate Platform

July 21 2021

Coave Therapeutics (pronounced ‘cove’; formerly Horama), a clinical stage biotechnology company focused on developing life […]